APP Pharmaceuticals is facing delays on inbound shipments and product releases of proposal, exacerbating the shortage situation and creating some back-orders for ASCs, according to an ASCA report.
APP has told the FDA they are committed to resolving the distribution challenges as quickly as possible. The FDA is working with all propofol manufacturers to ensure propofol can reach the market as soon as possible.
Learn more about ASCA.
Related Articles on Anesthesia:
AcelRx to Seek Approval for Pain Controlling Drug Device
Marine Corps Looks for Small Rugged Anesthesia Machines
Equity Firm Industry Experts Team Up to Form US Anesthesia Partners
APP has told the FDA they are committed to resolving the distribution challenges as quickly as possible. The FDA is working with all propofol manufacturers to ensure propofol can reach the market as soon as possible.
Learn more about ASCA.
Related Articles on Anesthesia:
AcelRx to Seek Approval for Pain Controlling Drug Device
Marine Corps Looks for Small Rugged Anesthesia Machines
Equity Firm Industry Experts Team Up to Form US Anesthesia Partners